These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 34528569)

  • 41. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
    Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
    Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Granulocytic myeloid-derived suppressor cells inhibit T follicular helper cells during experimental Schistosoma japonicum infection.
    Zhang Y; Wu Y; Liu H; Gong W; Hu Y; Shen Y; Cao J
    Parasit Vectors; 2021 Sep; 14(1):497. PubMed ID: 34565440
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
    Singh L; Muise ES; Bhattacharya A; Grein J; Javaid S; Stivers P; Zhang J; Qu Y; Joyce-Shaikh B; Loboda A; Zhang C; Meehl M; Chiang DY; Ranganath SH; Rosenzweig M; Brandish PE
    Mol Cancer Res; 2021 Apr; 19(4):702-716. PubMed ID: 33372059
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
    Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J
    Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249
    [No Abstract]   [Full Text] [Related]  

  • 45. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
    Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.
    Azzaoui I; Uhel F; Rossille D; Pangault C; Dulong J; Le Priol J; Lamy T; Houot R; Le Gouill S; Cartron G; Godmer P; Bouabdallah K; Milpied N; Damaj G; Tarte K; Fest T; Roussel M
    Blood; 2016 Aug; 128(8):1081-92. PubMed ID: 27338100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accumulation of circulating myeloid-derived suppressor cell subsets: predicting poor clinical efficacy and prognosis through T cell suppression in non-Hodgkin's lymphoma.
    Pu LF; Li MM; Feng XJ; Zhang T; Hu LH; Zheng HM; Charwudzi A; Ding YY; Liu J; Liu ZL; Xiong SD
    J Leukoc Biol; 2024 May; 115(6):1094-1107. PubMed ID: 38369808
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monocytic and granulocytic myeloid-derived suppressor cell plasticity and differentiation are organ-specific.
    Guha P; Gardell J; Rabinowitz B; Lopes M; DaSilva NA; Rowley D; Katz SC
    Oncogene; 2021 Jan; 40(3):693-704. PubMed ID: 33230244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
    Metzger P; Kirchleitner SV; Boehmer DFR; Hörth C; Eisele A; Ormanns S; Gunzer M; Lech M; Lauber K; Endres S; Duewell P; Schnurr M; König LM
    Cancer Immunol Immunother; 2020 Oct; 69(10):2101-2112. PubMed ID: 32448983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs.
    Porta C; Consonni FM; Morlacchi S; Sangaletti S; Bleve A; Totaro MG; Larghi P; Rimoldi M; Tripodo C; Strauss L; Banfi S; Storto M; Pressiani T; Rimassa L; Tartari S; Ippolito A; Doni A; Soldà G; Duga S; Piccolo V; Ostuni R; Natoli G; Bronte V; Balzac F; Turco E; Hirsch E; Colombo MP; Sica A
    Cancer Res; 2020 Jul; 80(13):2874-2888. PubMed ID: 32265223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Granulocytic subset of myeloid derived suppressor cells in rats with mammary carcinoma.
    Dolen Y; Gunaydin G; Esendagli G; Guc D
    Cell Immunol; 2015 May; 295(1):29-35. PubMed ID: 25732602
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors.
    Guan X; Liu Z; Zhang J; Jin X
    Adv Clin Exp Med; 2018 Jul; 27(7):947-953. PubMed ID: 29905412
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.
    Waight JD; Hu Q; Miller A; Liu S; Abrams SI
    PLoS One; 2011; 6(11):e27690. PubMed ID: 22110722
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monocytic-Myeloid Derived Suppressor Cells of HIV-Infected Individuals With Viral Suppression Exhibit Suppressed Innate Immunity to
    Namdev P; Patel S; Sparling B; Garg A
    Front Immunol; 2021; 12():647019. PubMed ID: 33995365
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.
    Apodaca MC; Wright AE; Riggins AM; Harris WP; Yeung RS; Yu L; Morishima C
    J Immunother Cancer; 2019 Aug; 7(1):230. PubMed ID: 31462270
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2).
    Soler DC; Kerstetter-Fogle A; Young AB; Rayman P; Finke JH; Debanne SM; Cooper KD; Barnholtz-Sloan J; Sloan AE; McCormick TS
    Mol Immunol; 2022 Feb; 142():1-10. PubMed ID: 34953280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
    Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
    J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer.
    Tavukcuoglu E; Horzum U; Yanik H; Uner A; Yoyen-Ermis D; Nural SK; Aydin B; Sokmensuer C; Karakoc D; Yilmaz KB; Hamaloglu E; Esendagli G
    Eur J Immunol; 2020 Dec; 50(12):2067-2074. PubMed ID: 32691408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL.
    Ferrer G; Jung B; Chiu PY; Aslam R; Palacios F; Mazzarello AN; Vergani S; Bagnara D; Chen SS; Yancopoulos S; Xochelli A; Yan XJ; Burger JA; Barrientos JC; Kolitz JE; Allen SL; Stamatopoulos K; Rai KR; Sherry B; Chiorazzi N
    Leukemia; 2021 Nov; 35(11):3163-3175. PubMed ID: 33935280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.